Base de dados : MEDLINE
Pesquisa : D27.505.696.663.050.495 [Categoria DeCS]
Referências encontradas : 979 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 98 ir para página                         

  1 / 979 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28729114
[Au] Autor:Lee H; Jung S; Lee P; Jeong Y
[Ad] Endereço:Department of Bio and Brain Engineering, KI for Health Science and Technology, KAIST, Daejeon, Republic of Korea.
[Ti] Título:Altered intrinsic functional connectivity in the latent period of epileptogenesis in a temporal lobe epilepsy model.
[So] Source:Exp Neurol;296:89-98, 2017 Oct.
[Is] ISSN:1090-2430
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The latent period, a seizure-free phase, is the duration between brain injury and the onset of spontaneous recurrent seizures (SRSs) during epileptogenesis. The latent period is thought to involve several progressive pathophysiological events that lead to the evolution of the chronic epilepsy phase. Hence, it is vital to investigate the changes in the latent period during epileptogenesis in order to better understand temporal lobe epilepsy (TLE), and to achieve early diagnosis and appropriate management of the condition. Accordingly, recent studies with patients with TLE using resting-state functional magnetic resonance imaging (rs-fMRI) have reported that alterations of resting-state functional connectivity (rsFC) during the chronic period are associated with some clinical manifestations, including learning and memory impairments, emotional instability, and social behavior deficits, in addition to repetitive seizure episodes. In contrast, the changes in the intrinsic rsFC during epileptogenesis, particularly during the latent period, remain unclear. In this study, we investigated the alterations in intrinsic rsFC during the latent and chronic periods in a pilocarpine-induced TLE mouse model using intrinsic optical signal imaging (IOSI). This technique can monitor the changes in the local hemoglobin concentration according to neuronal activity and can help investigate large-scale brain intrinsic networks. After seeding on the anatomical regions of interest (ROIs) and calculating the correlation coefficients between each ROI, we established and compared functional correlation matrices and functional connectivity maps during the latent and chronic periods of epilepsy. We found a decrease in the interhemispheric rsFC at the frontal and temporal regions during both the latent and chronic periods. Furthermore, a significant decrease in the interhemispheric rsFC was observed in the somatosensory area during the chronic period. Changes in network configurations during epileptogenesis were examined by graph theoretical network analysis. Interestingly, increase in the power of low frequency oscillations was observed during the latent period. These results suggest that, even if there are no apparent ictal seizure events during the latent period, there are ongoing changes in the rsFC in the epileptic brain. Furthermore, these results suggest that the pathophysiology of epilepsy may be related to widespread altered intrinsic functional connectivity. These findings can help enhance our understanding of epileptogenesis, and accordingly, changes in intrinsic functional connectivity can serve as an early diagnosis.
[Mh] Termos MeSH primário: Mapeamento Encefálico
Ondas Encefálicas/fisiologia
Epilepsia do Lobo Temporal/fisiopatologia
Vias Neurais/fisiologia
[Mh] Termos MeSH secundário: Animais
Ondas Encefálicas/efeitos dos fármacos
Modelos Animais de Doenças
Eletroencefalografia
Epilepsia do Lobo Temporal/induzido quimicamente
Epilepsia do Lobo Temporal/diagnóstico por imagem
Epilepsia do Lobo Temporal/patologia
Lateralidade Funcional
Hemodinâmica/efeitos dos fármacos
Processamento de Imagem Assistida por Computador
Camundongos
Camundongos Endogâmicos C57BL
Mióticos/toxicidade
Vias Neurais/diagnóstico por imagem
Neuroimagem
Pilocarpina/toxicidade
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Miotics); 01MI4Q9DI3 (Pilocarpine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE


  2 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28691801
[Au] Autor:Woolley MJ; Simms J; Uddin S; Poyner DR; Conner AC
[Ad] Endereço:College of Medical and Dental Sciences, University of Birmingham , Edgbaston, Birmingham B15 2TT, U.K.
[Ti] Título:Relative Antagonism of Mutants of the CGRP Receptor Extracellular Loop 2 Domain (ECL2) Using a Truncated Competitive Antagonist (CGRP ): Evidence for the Dual Involvement of ECL2 in the Two-Domain Binding Model.
[So] Source:Biochemistry;56(30):3877-3880, 2017 Aug 01.
[Is] ISSN:1520-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The second extracellular loop (ECL2) of the G protein-coupled receptor (GPCR) family is important for ligand interaction and drug discovery. ECL2 of the family B cardioprotective calcitonin gene-related peptide (CGRP) receptor is required for cell signaling. Family B GPCR ligands have two regions; the N-terminus mediates receptor activation, and the remainder confers high-affinity binding. Comparing antagonism of CGRP at a number of point mutations of ECL2 of the CGRP receptor, we show that the ECL2 potentially facilitates interaction with up to the 18 N-terminal residues of CGRP. This has implications for understanding family B GPCR activation and for drug design at the CGRP receptor.
[Mh] Termos MeSH primário: Peptídeo Relacionado com Gene de Calcitonina/farmacologia
Proteína Semelhante a Receptor de Calcitonina/agonistas
Mióticos/farmacologia
Modelos Moleculares
Fragmentos de Peptídeos/farmacologia
Proteína 1 Modificadora da Atividade de Receptores/metabolismo
Receptores de Peptídeo Relacionado com o Gene de Calcitonina/agonistas
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Substituição de Aminoácidos
Animais
Sítios de Ligação
Ligação Competitiva
Células COS
Peptídeo Relacionado com Gene de Calcitonina/química
Peptídeo Relacionado com Gene de Calcitonina/genética
Peptídeo Relacionado com Gene de Calcitonina/metabolismo
Proteína Semelhante a Receptor de Calcitonina/química
Proteína Semelhante a Receptor de Calcitonina/genética
Proteína Semelhante a Receptor de Calcitonina/metabolismo
Cercopithecus aethiops
Cinética
Ligantes
Mióticos/química
Mióticos/metabolismo
Fragmentos de Peptídeos/química
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/metabolismo
Mutação Puntual
Conformação Proteica
Domínios e Motivos de Interação entre Proteínas
Mapeamento de Interação de Proteínas
Multimerização Proteica
Proteína 1 Modificadora da Atividade de Receptores/química
Proteína 1 Modificadora da Atividade de Receptores/genética
Receptores de Peptídeo Relacionado com o Gene de Calcitonina/química
Receptores de Peptídeo Relacionado com o Gene de Calcitonina/genética
Receptores de Peptídeo Relacionado com o Gene de Calcitonina/metabolismo
Proteínas Recombinantes/química
Proteínas Recombinantes/metabolismo
Proteínas Recombinantes/farmacologia
Homologia Estrutural de Proteína
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CALCRL protein, human); 0 (Calcitonin Receptor-Like Protein); 0 (Ligands); 0 (Miotics); 0 (Peptide Fragments); 0 (RAMP1 protein, human); 0 (RCP9 protein, human); 0 (Receptor Activity-Modifying Protein 1); 0 (Receptors, Calcitonin Gene-Related Peptide); 0 (Recombinant Proteins); 119911-68-1 (calcitonin gene-related peptide (8-37)); 83652-28-2 (Calcitonin Gene-Related Peptide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.1021/acs.biochem.7b00077


  3 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27552499
[Au] Autor:Lin Z; Wu R; Moonasar N; Zhou Y
[Ad] Endereço:*The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China †Ophthalmology Department, University of the West Indies, St Augustine, Trinidad and Tobago.
[Ti] Título:Acute Primary Angle Closure in the Fellow Eye as a Complication of Facedown Position After Vitrectomy Surgery.
[So] Source:J Glaucoma;26(1):e5-e6, 2017 Jan.
[Is] ISSN:1536-481X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report a case of acute primary angle closure that developed in the fellow eye rapidly after facedown position after vitrectomy surgery. PATIENTS AND METHODS: A 66-year-old female developed acute primary angle closure in the fellow eye approximately 1.5 hours after facedown position after vitrectomy surgery for macular hole. RESULTS: The intraocular pressure was controlled after treatment that included halting the facedown position, intravenous mannitol injection, and topical pilocarpine instillation. Facedown position was continued after laser peripheral iridotomy was performed. The intraocular pressure was controlled within normal range even after pilocarpine was withdrawn. CONCLUSIONS: Although rare, the potential risk of acute-angle closure should be explicitly explained to patients being considered for facedown position after vitrectomy. Prophylactic intervention, such as laser peripheral iridotomy, could be considered for anatomically predisposed eyes.
[Mh] Termos MeSH primário: Glaucoma de Ângulo Fechado/etiologia
Decúbito Inclinado com Rebaixamento da Cabeça/efeitos adversos
Pressão Intraocular/fisiologia
Iris/cirurgia
Terapia a Laser/métodos
Pilocarpina/administração & dosagem
Vitrectomia/efeitos adversos
[Mh] Termos MeSH secundário: Doença Aguda
Administração Tópica
Idoso
Feminino
Glaucoma de Ângulo Fechado/fisiopatologia
Glaucoma de Ângulo Fechado/terapia
Seres Humanos
Mióticos/administração & dosagem
Perfurações Retinianas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Miotics); 01MI4Q9DI3 (Pilocarpine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.1097/IJG.0000000000000523


  4 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27347646
[Au] Autor:Skaat A; Rosman MS; Chien JL; Mogil RS; Ren R; Liebmann JM; Ritch R; Park SC
[Ad] Endereço:Moise and Chella Safra Advanced Ocular Imaging Laboratory, Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York2Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
[Ti] Título:Effect of Pilocarpine Hydrochloride on the Schlemm Canal in Healthy Eyes and Eyes With Open-Angle Glaucoma.
[So] Source:JAMA Ophthalmol;134(9):976-81, 2016 Sep 01.
[Is] ISSN:2168-6173
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:IMPORTANCE: The in vivo effect of pilocarpine hydrochloride on the Schlemm canal may help explain its pharmacologic mechanism of action and better indicate its clinical use. OBJECTIVE: To investigate the effect of pilocarpine on the structure of the Schlemm canal in vivo in healthy eyes and eyes with glaucoma. DESIGN, SETTING, AND PARTICIPANTS: In this case-control study, healthy individuals and patients with open-angle glaucoma were prospectively enrolled between September 1, 2013, and June 30, 2014, after a complete ophthalmologic examination at a tertiary glaucoma referral practice. Eighty-one serial, horizontal, enhanced depth imaging optical coherence tomographic B-scans (interval between B-scans, approximately 35 µm) of the nasal corneoscleral limbus were performed before and 1 hour after topical administration of pilocarpine, 1%, in 1 eye of healthy volunteers and pilocarpine, 2%, in 1 eye of patients with glaucoma. Fifty B-scans in the overlapping area (circumferential length, approximately 1.7 mm) between the 2 sets of serial scans (before and after pilocarpine administration) were selected for analysis based on the structures of aqueous and blood vessels as landmarks. The cross-sectional area of the Schlemm canal was measured in each selected B-scan. Volume of the Schlemm canal was calculated using commercially available 3-dimensional reconstruction software. MAIN OUTCOMES AND MEASURES: Mean cross-sectional area of the Schlemm canal. RESULTS: Enhanced depth imaging optical coherence tomographic scans of the Schlemm canal were performed successfully before and after administration of pilocarpine, 1%, in 9 healthy eyes (9 individuals) and pilocarpine, 2%, in 10 eyes with glaucoma (10 patients) (mean [SD] age, 31.9 [7.8] and 68.7 [13.2] years, respectively). Following pilocarpine administration, mean (SD) intraocular pressure decreased from 14.3 (1.3) to 13.7 (1.1) mm Hg in healthy eyes (P = .004) and from 17.5 (6.0) to 16.6 (6.1) mm Hg in eyes with glaucoma (P = .01). The mean (SD) cross-sectional area of the Schlemm canal increased by 21% (4667 [1704] to 5647 [1911] µm2) in healthy eyes (P < .001) and by 24% (3737 [679] to 4619 [692] µm2) in eyes with glaucoma (P < .001) (mean difference in percent increase, 2.2%; 95% CI, -8.5% to 12.9%). The mean (SD) volume of the Schlemm canal in the overlapping area increased from 8 004 000 (2 923 000) to 9 685 000 (3 277 000) µm3 in healthy eyes (P < .001) and from 6 468 000 (1 170 000) to 7 970 000 (1 199 000) µm3 in eyes with glaucoma (P < .001). CONCLUSIONS AND RELEVANCE: These data suggest that pilocarpine expands the Schlemm canal in eyes with and without glaucoma. No differences in the effect were identified between the 2 groups. Enhanced depth imaging optical coherence tomography may be useful in investigating the effect of pharmacologic agents on the Schlemm canal.
[Mh] Termos MeSH primário: Segmento Anterior do Olho/patologia
Glaucoma de Ângulo Aberto/tratamento farmacológico
Pressão Intraocular/efeitos dos fármacos
Pilocarpina/administração & dosagem
Tomografia de Coerência Óptica/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seguimentos
Glaucoma de Ângulo Aberto/diagnóstico
Glaucoma de Ângulo Aberto/fisiopatologia
Seres Humanos
Masculino
Meia-Idade
Mióticos/administração & dosagem
Soluções Oftálmicas
Estudos Retrospectivos
Tonometria Ocular
Malha Trabecular/patologia
Campos Visuais
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Miotics); 0 (Ophthalmic Solutions); 01MI4Q9DI3 (Pilocarpine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170522
[Lr] Data última revisão:
170522
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160628
[St] Status:MEDLINE
[do] DOI:10.1001/jamaophthalmol.2016.1881


  5 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27259559
[Au] Autor:Madea B
[Ad] Endereço:Institute of Forensic Medicine, University of Bonn, Stiftsplatz 12, 53111, Bonn, Germany. b.madea@uni-bonn.de.
[Ti] Título:Methods for determining time of death.
[So] Source:Forensic Sci Med Pathol;12(4):451-485, 2016 Dec.
[Is] ISSN:1556-2891
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Medicolegal death time estimation must estimate the time since death reliably. Reliability can only be provided empirically by statistical analysis of errors in field studies. Determining the time since death requires the calculation of measurable data along a time-dependent curve back to the starting point. Various methods are used to estimate the time since death. The current gold standard for death time estimation is a previously established nomogram method based on the two-exponential model of body cooling. Great experimental and practical achievements have been realized using this nomogram method. To reduce the margin of error of the nomogram method, a compound method was developed based on electrical and mechanical excitability of skeletal muscle, pharmacological excitability of the iris, rigor mortis, and postmortem lividity. Further increasing the accuracy of death time estimation involves the development of conditional probability distributions for death time estimation based on the compound method. Although many studies have evaluated chemical methods of death time estimation, such methods play a marginal role in daily forensic practice. However, increased precision of death time estimation has recently been achieved by considering various influencing factors (i.e., preexisting diseases, duration of terminal episode, and ambient temperature). Putrefactive changes may be used for death time estimation in water-immersed bodies. Furthermore, recently developed technologies, such as H magnetic resonance spectroscopy, can be used to quantitatively study decompositional changes. This review addresses the gold standard method of death time estimation in forensic practice and promising technological and scientific developments in the field.
[Mh] Termos MeSH primário: Medicina Legal/métodos
Mudanças Depois da Morte
[Mh] Termos MeSH secundário: Temperatura Corporal/fisiologia
Peso Corporal/fisiologia
Estimulação Elétrica
Conteúdo Gastrointestinal
Parada Cardíaca/fisiopatologia
Seres Humanos
Iris/fisiologia
Espectroscopia de Ressonância Magnética
Mióticos/farmacologia
Modelos Biológicos
Músculo Esquelético/fisiologia
Midriáticos/farmacologia
Músculos Oculomotores/efeitos dos fármacos
Potássio/metabolismo
Rigor Mortis/patologia
Fatores de Tempo
Ureia/metabolismo
Corpo Vítreo/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Miotics); 0 (Mydriatics); 8W8T17847W (Urea); RWP5GA015D (Potassium)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160605
[St] Status:MEDLINE


  6 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27026441
[Au] Autor:Sethi HS; Mayuresh NP; Gupta VS
[Ad] Endereço:From the Department of Ophthalmology, Vardhman Mahavir Medical College and Safdarjung Hospital, Ansari Nagar, New Delhi, India.
[Ti] Título:Intraoperative intracameral pilocarpine after capsular tension ring and capsule/iris hook insertion in pediatric eyes with subluxated cataract.
[So] Source:J Cataract Refract Surg;42(2):190-3, 2016 Feb.
[Is] ISSN:1873-4502
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Capsular tension rings and iris hooks have proved to be useful devices in cataract surgery in cases of zonular weakness and dialysis. We describe the use of intracameral pilocarpine-induced pupillary miosis to couple the iris and the capsulorhexis edge with iris hooks during phacoemulsification in pediatric cases with posttraumatic subluxated cataractous lens. The coupled iris and capsule act as a single unit, eliminating the space between them and significantly reducing the possibility of vitreous or ophthalmic viscosurgical device passing through the zonular defect. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
[Mh] Termos MeSH primário: Subluxação do Cristalino/cirurgia
Mióticos/administração & dosagem
Facoemulsificação/métodos
Pilocarpina/administração & dosagem
Implante de Prótese
Pupila/efeitos dos fármacos
[Mh] Termos MeSH secundário: Câmara Anterior/cirurgia
Catarata/etiologia
Traumatismos Oculares/etiologia
Traumatismos Oculares/cirurgia
Seres Humanos
Cuidados Intraoperatórios
Subluxação do Cristalino/etiologia
Cristalino/lesões
Facoemulsificação/instrumentação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Miotics); 01MI4Q9DI3 (Pilocarpine)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160331
[St] Status:MEDLINE


  7 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26905690
[Au] Autor:Hoang TA; Macdonnell JE; Mangan MC; Monsour CS; Polwattage BL; Wilson SF; Suheimat M; Atchison DA
[Ad] Endereço:*BVisSc, MOptom †PhD ‡DSc School of Optometry & Vision Sciences and Institute of Health & Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Queensland, Australia (all authors).
[Ti] Título:Time Course of Pupil Center Location after Ocular Drug Application.
[So] Source:Optom Vis Sci;93(6):594-9, 2016 Jun.
[Is] ISSN:1538-9235
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To investigate the time course of pupil centration after application of common topical ocular drugs. METHODS: Single drops of 2.5% phenylephrine hydrochloride, 1% tropicamide, and 2% pilocarpine hydrochloride were applied on different days to the right eyes of 12 participants. Anterior eye images were captured, at 5-min intervals for an hour, using an infrared-sensitive camera. The images were analyzed to determine pupil diameter and pupil center, the latter with respect to the limbal center. As a control, natural pupil size and pupil center were determined under different illuminances. RESULTS: Pupil centers of natural pupils shifted temporally as pupils dilated. At common pupil sizes, drug-induced pupil centers were different from natural pupil centers. Phenylephrine produced a center shift in the nasal and inferior directions that peaked after a mean of 30 min, whereas dilation was continuing up to 60 min. Tropicamide produced transient center shifts in the nasal and inferior directions that peaked at about 10 min before reducing toward baseline values, whereas dilation reached a peak at about 25 min. Pilocarpine produced a small sustained superior shift that, like constriction, reached a peak after about 25 min. CONCLUSIONS: Application of topical ophthalmic drugs cause shifts in pupil center that do not match those produced by natural changes in pupil size and that, in the cases of phenylephrine and tropicamide, follow a different time course than the pupil size changes.
[Mh] Termos MeSH primário: Mióticos/administração & dosagem
Midriáticos/administração & dosagem
Pupila/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acomodação Ocular/fisiologia
Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Soluções Oftálmicas
Fenilefrina/administração & dosagem
Pilocarpina/administração & dosagem
Fatores de Tempo
Tropicamida/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Miotics); 0 (Mydriatics); 0 (Ophthalmic Solutions); 01MI4Q9DI3 (Pilocarpine); 1WS297W6MV (Phenylephrine); N0A3Z5XTC6 (Tropicamide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160225
[St] Status:MEDLINE
[do] DOI:10.1097/OPX.0000000000000837


  8 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26874433
[Au] Autor:Larpkrajang S; Worasuwannarak W; Peonim V; Udnoon J; Srisont S
[Ad] Endereço:Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
[Ti] Título:The use of pilocarpine eye drops for estimating the time since death.
[So] Source:J Forensic Leg Med;39:100-3, 2016 Apr.
[Is] ISSN:1878-7487
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this study was to estimate the time since death using pilocarpine eye drops. METHODS: In this study, 100 postmortem cases with known time of death were included. In each case, the left pupil was measured in millimeter units using a vernier caliper, and pilocarpine eye drops were applied. The pupil was measured again 10 min later, and statistical analysis was used to analyze the correlation between the time since death and the change in the pupil. RESULTS: The longest duration since death that the pupils showed reaction to pilocarpine was 15 h. The correlation between the change in the pupil and the postmortem interval was found (Spearman's rho, r = -0.304, p = 0.002), and the change in the pupil may be used to predict the postmortem interval by the following regression equation: postmortem interval (PMI) = 8.310-3.702 (Diff) ± 0.735 (PMI was postmortem interval in hours and Diff was the difference in the size of the pupil after administering pilocarpine in millimeter units). CONCLUSION: The present study showed that pilocarpine eye drops can be used to estimate the time since death.
[Mh] Termos MeSH primário: Mióticos/administração & dosagem
Soluções Oftálmicas
Pilocarpina/administração & dosagem
Mudanças Depois da Morte
Pupila/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Patologia Legal
Seres Humanos
Masculino
Meia-Idade
Análise de Regressão
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Miotics); 0 (Ophthalmic Solutions); 01MI4Q9DI3 (Pilocarpine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170107
[Lr] Data última revisão:
170107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160215
[St] Status:MEDLINE


  9 / 979 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26828672
[Au] Autor:Agban Y; Lian J; Prabakar S; Seyfoddin A; Rupenthal ID
[Ad] Endereço:Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand; School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 9
[Ti] Título:Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride.
[So] Source:Int J Pharm;501(1-2):96-101, 2016 Mar 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Glaucoma is a common progressive eye disorder which remains the second leading cause of blindness worldwide. Current therapy involves frequent administration of eye drops which often results in poor patient adherence and therapeutic outcomes. The aim of this study was to overcome these limitations by developing a novel nanoparticle cross-linked collagen shield for sustained delivery of pilocarpine hydrochloride (PHCl). Three metal oxide nanoparticles (NPs); titanium dioxide (TiO2), zinc oxide (ZnO) and polyvinylpyrrolidone (PVP) capped zinc oxide (ZnO/PVP), were evaluated for their cytotoxicity as well as shield transparency before selecting ZnO/PVP NPs as the ideal candidate. Cross-linked collagen shields were then characterized for their mechanical strength, swelling capacity and bioadhesive properties, with ZnO/PVP NP cross-linked shields showing the most favorable characteristics compared to plain films. The shield with the best properties was then loaded with PHCl and in vitro release of zinc ions as well as PHCl was measured without and with further cross-linking by ultraviolet irradiation. The concentration of zinc ions released was well below the IC50 rendering them safe for ocular use. Moreover, collagen shields cross-linked with ZnO/PVP NPs released PHCl over a period of 14 days offering a promising sustained release treatment option for glaucoma.
[Mh] Termos MeSH primário: Colágeno/administração & dosagem
Nanopartículas Metálicas/administração & dosagem
Pilocarpina/administração & dosagem
Povidona/administração & dosagem
Titânio/administração & dosagem
Óxido de Zinco/administração & dosagem
[Mh] Termos MeSH secundário: Adesividade
Animais
Bovinos
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Colágeno/química
Córnea/química
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/química
Seres Humanos
Nanopartículas Metálicas/química
Mióticos/administração & dosagem
Mióticos/química
Pilocarpina/química
Povidona/química
Titânio/química
Óxido de Zinco/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Miotics); 01MI4Q9DI3 (Pilocarpine); 15FIX9V2JP (titanium dioxide); 9007-34-5 (Collagen); D1JT611TNE (Titanium); FZ989GH94E (Povidone); SOI2LOH54Z (Zinc Oxide)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160202
[St] Status:MEDLINE


  10 / 979 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:26978873
[Au] Autor:Neacsu AM
[Ti] Título:IMPORTANCE OF DEMOGRAPHIC RISK FACTORS FOR PRIMARY ANGLE CLOSURE.
[So] Source:Rom J Ophthalmol;59(2):112-5, 2015 Apr-Jun.
[Is] ISSN:2457-4325
[Cp] País de publicação:Romania
[La] Idioma:eng
[Ab] Resumo:According to the Guidelines of the European Glaucoma Society (fourth edition), the family history in the closing angle is an important factor that makes the family screening vital in these families. It is present in the clinical case in which two twin patients in different circumstances show the same symptoms of angle closure.
[Mh] Termos MeSH primário: Anti-Hipertensivos/administração & dosagem
Tartarato de Brimonidina/administração & dosagem
Glaucoma de Ângulo Fechado/diagnóstico
Glaucoma de Ângulo Fechado/terapia
Iridectomia
Anamnese
Mióticos/administração & dosagem
Pilocarpina/administração & dosagem
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Diagnóstico Diferencial
Quimioterapia Combinada
Feminino
Glaucoma de Ângulo Fechado/complicações
Seres Humanos
Hiperopia/complicações
Fatores de Risco
Resultado do Tratamento
Gêmeos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; TWIN STUDY
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Miotics); 01MI4Q9DI3 (Pilocarpine); 4S9CL2DY2H (Brimonidine Tartrate)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:160316
[Lr] Data última revisão:
160316
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160317
[St] Status:MEDLINE



página 1 de 98 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde